Fig. 1: Kaplan–Meier curves of overall survival (OS) and progression-free survival (PFS) according to development of any grade of irAEs prior to cycle 5.

a OS whole cohort, shaded areas showing 95% CI (N = 144), b Kaplan–Meier of OS specific to recipients of cICB therapy (N = 63), c Kaplan–Meier of OS specific to recipients of sICB therapy (N = 81), d 12-week landmark analysis for Oxford OS according to irAEs prior to cycle 5 (N = 133). All P-values refer to log-rank test.